An open-label, non comparative, two arm phase II trial of ZD1839 (Iressa) in patients with hormone-insensitive (ER and PgR negative) or hormone-resistant (ER and/or PgR positive) metastatic or inoperable locally advanced breast cancer
Study identifier:1839IL/0067
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open-label, non comparative, two arm phase II trial of ZD1839 (Iressa) in patients with hormone-insensitive (ER and PgR negative) or hormone-resistant (ER and/or PgR positive) metastatic or inoperable locally advanced breast cancer
Medical condition
-
Phase
Phase 2
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jul 2002
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
